Issue

Vol. 15 (2023)

Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy

https://doi.org/10.1007/s40820-023-01018-4
Qingfei Zhang
Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Hepatobiliary Institute of Nanjing University, Nanjing 210008, People’s Republic of China
Gaizhen Kuang
Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Hepatobiliary Institute of Nanjing University, Nanjing 210008, People’s Republic of China
Wenzhao Li
Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Hepatobiliary Institute of Nanjing University, Nanjing 210008, People’s Republic of China
Jinglin Wang
Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Hepatobiliary Institute of Nanjing University, Nanjing 210008, People’s Republic of China
Haozhen Ren
Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Hepatobiliary Institute of Nanjing University, Nanjing 210008, People’s Republic of China
Yuanjin Zhao
Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Hepatobiliary Institute of Nanjing University, Nanjing 210008, People’s Republic of China

Corresponding Author: Yuanjin Zhao

yjzhao@njglyy.com

Nano-Micro Letters, Vol. 15 (2023), Article Number: 44

Abstract

Gene therapy provides a promising approach in treating cancers with high efficacy and selectivity and few adverse effects. Currently, the development of functional vectors with safety and effectiveness is the intense focus for improving the delivery of nucleic acid drugs for gene therapy. For this purpose, stimuli-responsive nanocarriers displayed strong potential in improving the overall efficiencies of gene therapy and reducing adverse effects via effective protection, prolonged blood circulation, specific tumor accumulation, and controlled release profile of nucleic acid drugs. Besides, synergistic therapy could be achieved when combined with other therapeutic regimens. This review summarizes recent advances in various stimuli-responsive nanocarriers for gene delivery. Particularly, the nanocarriers responding to endogenous stimuli including pH, reactive oxygen species, glutathione, and enzyme, etc., and exogenous stimuli including light, thermo, ultrasound, magnetic field, etc., are introduced. Finally, the future challenges and prospects of stimuli-responsive gene delivery nanocarriers toward potential clinical translation are well discussed. The major objective of this review is to present the biomedical potential of stimuli-responsive gene delivery nanocarriers for cancer therapy and provide guidance for developing novel nanoplatforms that are clinically applicable.


Highlights:


1 Stimuli-responsive gene delivery nanocarriers (GDNCs) possess huge potential in the gene therapy field owing to their effective protection, prolonged blood circulation, selective and targeted delivery, and controlled release of nucleic acid drugs.
2 Recent advances in stimuli-responsive GDNCs for cancer therapy are classified, summarized, and exhibited by representative examples.
3 The potential challenges and prospects of stimuli-responsive GDNCs toward clinical translation are outlined and the future research directions are outlooked.

Keywords

Stimuli-responsive Nanocarrier Gene therapy Gene delivery Cancer
Zhang, Qingfei, Gaizhen Kuang, Wenzhao Li, Jinglin Wang, Haozhen Ren, and Yuanjin Zhao. 2023. “Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy”. Nano-Micro Letters 15 (February):44. https://doi.org/10.1007/s40820-023-01018-4.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram et al., Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J. Clin. 71(3), 209–249 (2021). https://doi.org/10.3322/caac.21660
  2. Y. Wang, X. Ma, W. Zhou, C. Liu, H. Zhang, Reregulated mitochondrial dysfunction reverses cisplatin resistance microenvironment in colorectal cancer. Smart Med. 1(1), 20220013 (2022). https://doi.org/10.1002/SMMD.20220013
  3. Y. Yang, P. Jin, X. Zhang, N. Ravichandran, H. Ying et al., New epigallocatechin gallate (EGCG) nanocomplexes co-assembled with 3-mercapto-1-hexanol and β-lactoglobulin for improvement of antitumor activity. J. Biomed. Nanotechnol. 13(7), 805–814 (2017). https://doi.org/10.1166/jbn.2017.2400
  4. D. Zhang, D. Zhong, J. Ouyang, J. He, Y. Qi et al., Microalgae-based oral microcarriers for gut microbiota homeostasis and intestinal protection in cancer radiotherapy. Nat. Commun. 13(1), 1413 (2022). https://doi.org/10.1038/s41467-022-28744-4
  5. Q. Zhang, G. Kuang, L. Zhang, Y. Zhu, Nanocarriers for platinum drug delivery. Biomed. Technol. 2, 77–89 (2023). https://doi.org/10.1016/j.bmt.2022.11.011
  6. L. Lei, B. Ma, C. Xu, H. Liu, Emerging tumor-on-chips with electrochemical biosensors. Trac-Trend. Anal. Chem. 153, 116640 (2022). https://doi.org/10.1016/j.trac.2022.116640
  7. X. Zhang, X. Chen, Y. Zhao, Nanozymes: versatile platforms for cancer diagnosis and therapy. Nano-Micro Lett. 14(1), 95 (2022). https://doi.org/10.1007/s40820-022-00828-2
  8. M.E. Davis, Non-viral gene delivery systems. Curr. Opin. Biotechnol. 13(2), 128–131 (2002). https://doi.org/10.1016/S0958-1669(02)00294-X
  9. B. Vogelstein, K.W. Kinzler, Cancer genes and the pathways they control. Nat. Med. 10(8), 789–799 (2004). https://doi.org/10.1038/nm1087
  10. P.Y. Teo, W. Cheng, J.L. Hedrick, Y.Y. Yang, Co-delivery of drugs and plasmid DNA for cancer therapy. Adv. Drug Delivery Rev. 98, 41–63 (2016). https://doi.org/10.1016/j.addr.2015.10.014
  11. L. Naldini, Gene therapy returns to centre stage. Nature 526(7573), 351–360 (2015). https://doi.org/10.1038/nature15818
  12. L. Jin, X. Zeng, M. Liu, Y. Deng, N. He, Current progress in gene delivery technology based on chemical methods and nano-carriers. Theranostics 4(3), 240 (2014). https://doi.org/10.7150/thno.6914
  13. M.H. Amer, Gene therapy for cancer: present status and future perspective. Mol. Cell. Ther. 2(1), 1–19 (2014). https://doi.org/10.1186/2052-8426-2-27
  14. Z. Yang, D. Gao, Z. Cao, C. Zhang, D. Cheng et al., Drug and gene co-delivery systems for cancer treatment. Biomater. Sci. 3(7), 1035–1049 (2015). https://doi.org/10.1039/c4bm00369a
  15. H.J. Kim, A. Kim, K. Miyata, K. Kataoka, Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv. Drug Delivery Rev. 104, 61–77 (2016). https://doi.org/10.1016/j.addr.2016.06.011
  16. Z. Zhou, X. Liu, D. Zhu, Y. Wang, Z. Zhang et al., Nonviral cancer gene therapy: delivery cascade and vector nanoproperty integration. Adv. Drug Delivery Rev. 115, 115–154 (2017). https://doi.org/10.1016/j.addr.2017.07.021
  17. J.E. Zuckerman, M.E. Davis, Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat. Rev. Drug Discov. 14(12), 843–856 (2015). https://doi.org/10.1038/nrd4685
  18. X. Huang, G. Wu, C. Liu, X. Hua, Z. Tang et al., Intercalation-driven formation of siRNA nanogels for cancer therapy. Nano Lett. 21(22), 9706–9714 (2021). https://doi.org/10.1021/acs.nanolett.1c03539
  19. E.P. Thi, C.E. Mire, A.C.H. Lee, J.B. Geisbert, J.Z. Zhou et al., Lipid nanop siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 521(7552), 362–365 (2015). https://doi.org/10.1038/nature14442
  20. L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal et al., Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29(4), 341–345 (2011). https://doi.org/10.1038/nbt.1807
  21. E. Uhlmann, A. Peyman, Antisense oligonucleotides: a new therapeutic principle. Chem. Rev. 90(4), 543–584 (1990). https://doi.org/10.1021/cr00102a001
  22. A. De Mesmaeker, R. Haener, P. Martin, H.E. Moser, Antisense oligonucleotides. Acc. Chem. Res. 28(9), 366–374 (1995). https://doi.org/10.1021/ar00057a002
  23. M.D. Jansson, A.H. Lund, MicroRNA and cancer. Mol. Oncol. 6(6), 590–610 (2012). https://doi.org/10.1016/j.molonc.2012.09.006
  24. G.A. Calin, C.M. Croce, MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 66(15), 7390–7394 (2006). https://doi.org/10.1158/0008-5472.CAN-06-0800
  25. Y. Xiao, Z. Tang, X. Huang, W. Chen, J. Zhou et al., Emerging mRNA technologies: delivery strategies and biomedical applications. Chem. Soc. Rev. 51(10), 3828–3845 (2022). https://doi.org/10.1039/d1cs00617g
  26. N. Kong, R. Zhang, G. Wu, X. Sui, J. Wang et al., Intravesical delivery of KDM6A-mRNA via mucoadhesive nanops inhibits the metastasis of bladder cancer. Proc. Nat. Acad. Sci. (2022). https://doi.org/10.1073/pnas.2112696119
  27. W. Tao, N.A. Peppas, Robotic pills for gastrointestinal-tract-targeted oral mRNA delivery. Matter 5(3), 775–777 (2022). https://doi.org/10.1016/j.matt.2022.02.008
  28. N. Kong, W. Tao, X. Ling, J. Wang, Y. Xiao et al., Synthetic mRNA nanop-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. Sci. Transl. Med. 11(523), eaaw1565 (2019). https://doi.org/10.1126/scitranslmed.aaw1565
  29. D.O. Lopez-Cantu, X. Wang, H. Carrasco-Magallanes, S. Afewerki, X. Zhang et al., From bench to the clinic: The path to translation of nanotechnology-enabled mRNA SARS-CoV-2 vaccines. Nano-Micro Lett. 14(1), 41 (2022). https://doi.org/10.1007/s40820-021-00771-8
  30. L. Wu, W. Zhou, L. Lin, A. Chen, J. Feng et al., Delivery of therapeutic oligonucleotides in nanoscale. Bioact. Mater. 7, 292–323 (2022). https://doi.org/10.1016/j.bioactmat.2021.05.038
  31. D. Zhang, L. Cai, X. Wei, Y. Wang, L. Shang et al., Multiplexed CRISPR/Cas9 quantifications based on bioinspired photonic barcodes. Nano Today 40, 101268 (2021). https://doi.org/10.1016/j.nantod.2021.101268
  32. C. Wu, Z. Chen, C. Li, Y. Hao, Y. Tang et al., CRISPR-Cas12a-empowered electrochemical biosensor for rapid and ultrasensitive detection of SARS-CoV-2 Delta variant. Nano-Micro Lett. 14(1), 159 (2022). https://doi.org/10.1007/s40820-022-00888-4
  33. Y. Liu, C.F. Xu, S. Iqbal, X.Z. Yang, J. Wang, Responsive nanocarriers as an emerging platform for cascaded delivery of nucleic acids to cancer. Adv. Drug Delivery Rev. 115, 98–114 (2017). https://doi.org/10.1016/j.addr.2017.03.004
  34. A.I. van den Berg, C.-O. Yun, R.M. Schiffelers, W.E. Hennink, Polymeric delivery systems for nucleic acid therapeutics: approaching the clinic. J. Control. Release 331, 121–141 (2021). https://doi.org/10.1016/j.jconrel.2021.01.014
  35. L. Li, L. Song, X. Liu, X. Yang, X. Li et al., Artificial virus delivers CRISPR-Cas9 system for genome editing of cells in mice. ACS Nano 11(1), 95–111 (2017). https://doi.org/10.1021/acsnano.6b04261
  36. A.J. Mellott, M.L. Forrest, M.S. Detamore, Physical non-viral gene delivery methods for tissue engineering. Ann. Biomed. Eng. 41(3), 446–468 (2013). https://doi.org/10.1007/s10439-012-0678-1
  37. J. Yang, Q. Zhang, H. Chang, Y. Cheng, Surface-engineered dendrimers in gene delivery. Chem. Rev. 115(11), 5274–5300 (2015). https://doi.org/10.1021/cr500542t
  38. J. Pahle, W. Walther, Vectors and strategies for nonviral cancer gene therapy. Exp. Opin. Biolog. Ther. 16(4), 443–461 (2016). https://doi.org/10.1517/14712598.2016.1134480
  39. X. Zhang, L. Hai, Y. Gao, G. Yu, Y. Sun, Lipid nanomaterials-based RNA therapy and cancer treatment. Acta Pharm. Sin. B (2022). https://doi.org/10.1016/j.apsb.2022.10.004
  40. X. Huang, E. Kon, X. Han, X. Zhang, N. Kong et al., Nanotechnology-based strategies against SARS-CoV-2 variants. Nat. Nanotechnol. 17(10), 1027–1037 (2022). https://doi.org/10.1038/s41565-022-01174-5
  41. Y. Liu, W. Wu, Y. Wang, S. Han, Y. Yuan et al., Recent development of gene therapy for pancreatic cancer using non-viral nanovectors. Biomater. Sci. 9(20), 6673–6690 (2021). https://doi.org/10.1039/D1BM90082J
  42. R. Mohammadinejad, A. Dehshahri, V.S. Madamsetty, M. Zahmatkeshan, S. Tavakol et al., In vivo gene delivery mediated by non-viral vectors for cancer therapy. J. Control. Release 325, 249–275 (2020). https://doi.org/10.1016/j.jconrel.2020.06.038
  43. H. Yin, R.L. Kanasty, A.A. Eltoukhy, A.J. Vegas, J.R. Dorkin et al., Non-viral vectors for gene-based therapy. Nat. Rev. Gen. 15(8), 541–555 (2014). https://doi.org/10.1038/nrg3763
  44. Q. Sun, Z. Wang, B. Liu, F. He, S. Gai et al., Recent advances on endogenous/exogenous stimuli-triggered nanoplatforms for enhanced chemodynamic therapy. Coord. Chem. Rev. 451, 214267 (2022). https://doi.org/10.1016/j.ccr.2021.214267
  45. Y. Yang, H. Wu, B. Liu, Z. Liu, Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment. Adv. Drug Deliv. Rev. 179, 114004 (2021). https://doi.org/10.1016/j.addr.2021.114004
  46. Y. Chen, D. Qin, J. Zou, X. Li, X.D. Guo et al., Living leukocyte-based drug delivery systems. Adv. Mater. (2022). https://doi.org/10.1002/adma.202207787
  47. B.E. Ferdows, D.N. Patel, W. Chen, X. Huang, N. Kong et al., RNA cancer nanomedicine: Nanotechnology-mediated RNA therapy. Nanoscale 14(12), 4448–4455 (2022). https://doi.org/10.1039/d1nr06991h
  48. X. Huang, N. Kong, X. Zhang, Y. Cao, R. Langer et al., The landscape of mRNA nanomedicine. Nat. Med. 28(11), 2273–2287 (2022). https://doi.org/10.1038/s41591-022-02061-1
  49. Z. Tang, N. Kong, X. Zhang, Y. Liu, P. Hu et al., A materials-science perspective on tackling COVID-19. Nat. Rev. Mater. 5(11), 847–860 (2020). https://doi.org/10.1038/s41578-020-00247-y
  50. H. Ruan, Y. Li, C. Wang, Y. Jiang, Y. Han et al., Click chemistry extracellular vesicle/peptide/chemokine nanocarriers for treating central nervous system injuries. Acta Pharm. Sin. B (2022). https://doi.org/10.1016/j.apsb.2022.06.007
  51. X. Jing, H. Hu, Y. Sun, B. Yu, H. Cong et al., The intracellular and extracellular microenvironment of tumor site: The trigger of stimuli-responsive drug delivery systems. Small Meth. 6(3), 2101437 (2022). https://doi.org/10.1002/smtd.202101437
  52. P.E. Saw, H. Yao, C. Lin, W. Tao, O.C. Farokhzad et al., Stimuli-responsive polymer-prodrug hybrid nanoplatform for multistage siRNA delivery and combination cancer therapy. Nano Lett. 19(9), 5967–5974 (2019). https://doi.org/10.1021/acs.nanolett.9b01660
  53. C. He, D. Liu, W. Lin, Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer. Biomaterials 36, 124–133 (2015). https://doi.org/10.1016/j.biomaterials.2014.09.017
  54. Y. Wu, J. Zheng, Q. Zeng, T. Zhang, D. Xing, Light-responsive charge-reversal nanovector for high-efficiency in vivo CRISPR/Cas9 gene editing with controllable location and time. Nano Res. 13(9), 2399–2406 (2020). https://doi.org/10.1007/s12274-020-2864-z
  55. C. Yu, B. Ding, X. Zhang, X. Deng, K. Deng et al., Targeted iron nanops with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo. Biomaterials 155, 112–123 (2018). https://doi.org/10.1016/j.biomaterials.2017.11.014
  56. M. Furtado, L. Chen, Z. Chen, A. Chen, W. Cui, Development of fish collagen in tissue regeneration and drug delivery. Eng. Reg. 3(3), 217–231 (2022). https://doi.org/10.1016/j.engreg.2022.05.002
  57. G. Chen, A.A. Abdeen, Y. Wang, P.K. Shahi, S. Robertson et al., A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing. Nat. Nanotechnol. 14(10), 974–980 (2019). https://doi.org/10.1038/s41565-019-0539-2
  58. K. Lee, M. Conboy, H.M. Park, F. Jiang, H.J. Kim et al., Nanop delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat. Biomed. Eng. 1, 889–901 (2017). https://doi.org/10.1038/s41551-017-0137-2
  59. H. Lu, Q. Zhang, S. He, S. Liu, Z. Xie et al., Reduction-sensitive fluorinated-Pt(IV) universal transfection nanoplatform facilitating CT45-targeted CRISPR/dCas9 activation for synergistic and individualized treatment of ovarian cancer. Small 17(41), 2102494 (2021). https://doi.org/10.1002/smll.202102494
  60. J. Wang, X. He, S. Shen, Z. Cao, X. Yang, ROS-sensitive cross-linked polyethylenimine for red-light-activated siRNA therapy. ACS Appl. Mater. Interfaces 11(2), 1855–1863 (2019). https://doi.org/10.1021/acsami.8b18697
  61. J. Wang, H. He, X. Xu, X. Wang, Y. Chen et al., Far-red light-mediated programmable anti-cancer gene delivery in cooperation with photodynamic therapy. Biomaterials 171, 72–82 (2018). https://doi.org/10.1016/j.biomaterials.2018.04.020
  62. K. Han, Q. Lei, H.-Z. Jia, S.-B. Wang, W.-N. Yin et al., A tumor targeted chimeric peptide for synergistic endosomal escape and therapy by dual-stage light manipulation. Adv. Funct. Mater. 25(8), 1248–1257 (2015). https://doi.org/10.1002/adfm.201403190
  63. X. Chen, Y. Chen, H. Xin, T. Wan, Y. Ping, Near-infrared optogenetic engineering of photothermal nanocrispr for programmable genome editing. Proc. Nat. Acad. Sci. USA 117(5), 2395–2405 (2020). https://doi.org/10.1073/pnas.1912220117
  64. X. Wang, X. Xiao, Y. Feng, J. Li, Y. Zhang, A photoresponsive antibody-siRNA conjugate for activatable immunogene therapy of cancer. Chem. Sci. 13(18), 5345–5352 (2022). https://doi.org/10.1039/d2sc01672a
  65. Y. Wang, S. Li, P. Zhang, H. Bai, L. Feng et al., Photothermal-responsive conjugated polymer nanops for remote control of gene expression in living cells. Adv. Mater. 30(8), 1705418 (2018). https://doi.org/10.1002/adma.201705418
  66. Z. Yang, D. Gao, X. Guo, L. Jin, J. Zheng et al., Fighting immune cold and reprogramming immunosuppressive tumor microenvironment with red blood cell membrane-camouflaged nanobullets. ACS Nano 14(12), 17442–17457 (2020). https://doi.org/10.1021/acsnano.0c07721
  67. Y. Wang, D. Gao, Y. Liu, X. Guo, S. Chen et al., Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicine. Bioact. Mater. 6(6), 1513–1527 (2021). https://doi.org/10.1016/j.bioactmat.2020.11.016
  68. D. Gao, T. Chen, S. Chen, X. Ren, Y. Han et al., Targeting hypoxic tumors with hybrid nanobullets for oxygen-independent synergistic photothermal and thermodynamic therapy. Nano-Micro Lett. 13(1), 99 (2021). https://doi.org/10.1007/s40820-021-00616-4
  69. D. Gao, Y. Shi, J. Ni, S. Chen, Y. Wang et al., NIR/MRI-guided oxygen-independent carrier-free anti-tumor nano-theranostics. Small 18(36), 2106000 (2022). https://doi.org/10.1002/smll.202106000
  70. L. Jin, X. Guo, D. Gao, Y. Liu, J. Ni et al., An NIR photothermal-responsive hybrid hydrogel for enhanced wound healing. Bioact. Mater. 16, 162–172 (2022). https://doi.org/10.1016/j.bioactmat.2022.03.006
  71. D. Gao, X. Guo, X. Zhang, S. Chen, Y. Wang et al., Multifunctional phototheranostic nanomedicine for cancer imaging and treatment. Mater. Today Bio 5, 100035 (2020). https://doi.org/10.1016/j.mtbio.2019.100035
  72. Z. Yang, J. Zhao, G. Yang, M. Guo, Y. Wang et al., Thermal immuno-nanomedicine in cancer. Nat. Rev. Clin. Oncol. (2023). https://doi.org/10.1038/s41571-022-00717-y
  73. Y. Wu, D. Zhou, Q. Zhang, Z. Xie, X. Chen et al., Dual-sensitive charge-conversional polymeric prodrug for efficient codelivery of demethylcantharidin and doxorubicin. Biomacromol 17(8), 2650–2661 (2016). https://doi.org/10.1021/acs.biomac.6b00705
  74. M. Zhou, X. Zhang, J. Xie, R. Qi, H. Lu et al., pH-sensitive poly(β-amino ester)s nanocarriers facilitate the inhibition of drug resistance in breast cancer cells. Nanomaterials 8(11), 952 (2018). https://doi.org/10.3390/nano8110952
  75. F.J. Voskuil, P.J. Steinkamp, T. Zhao, B. van der Vegt, M. Koller et al., Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery. Nat. Commun. 11(1), 3257 (2020). https://doi.org/10.1038/s41467-020-16814-4
  76. B. Chen, L. Mei, R. Fan, Y. Wang, C. Nie et al., Facile construction of targeted pH-responsive DNA-conjugated gold nanops for synergistic photothermal-chemotherapy. Chin. Chem. Lett. 32(5), 1775–1779 (2021). https://doi.org/10.1016/j.cclet.2020.12.058
  77. Q. Zhang, S. He, G. Kuang, S. Liu, H. Lu et al., Morphology tunable and acid-sensitive dextran-doxorubicin conjugate assemblies for targeted cancer therapy. J. Mater. Chem. B 8(31), 6898–6904 (2020). https://doi.org/10.1039/d0tb00746c
  78. S. Li, Z.T. Bennett, B.D. Sumer, J. Gao, Nano-immune-engineering approaches to advance cancer immunotherapy: Lessons from ultra-pH-sensitive nanops. Acc. Chem. Res. 53(11), 2546–2557 (2020). https://doi.org/10.1021/acs.accounts.0c00475
  79. L. Liang, L. Wen, Y. Weng, J. Song, H. Li et al., Homologous-targeted and tumor microenvironment-activated hydroxyl radical nanogenerator for enhanced chemoimmunotherapy of non-small cell lung cancer. Chem. Eng. J. 425, 131451 (2021). https://doi.org/10.1016/j.cej.2021.131451
  80. J.-Z. Du, X.-J. Du, C.-Q. Mao, J. Wang, Tailor-made dual pH-sensitive polymer-doxorubicin nanops for efficient anticancer drug delivery. J. Am. Chem. Soc. 133(44), 17560–17563 (2011). https://doi.org/10.1021/ja207150n
  81. J.-Z. Du, C.-Q. Mao, Y.-Y. Yuan, X.-Z. Yang, J. Wang, Tumor extracellular acidity-activated nanops as drug delivery systems for enhanced cancer therapy. Biotechnol. Adv. 32(4), 789–803 (2014). https://doi.org/10.1016/j.biotechadv.2013.08.002
  82. P. Mi, D. Kokuryo, H. Cabral, H. Wu, Y. Terada et al., A pH-activatable nanop with signal-amplification capabilities for non-invasive imaging of tumour malignancy. Nat. Nanotechnol. 11(8), 724–730 (2016). https://doi.org/10.1038/nnano.2016.72
  83. G. Lian, J.R. Gnanaprakasam, Glutathione de novo synthesis but not recycling process coordinates with glutamine catabolism to control redox homeostasis and directs murine T cell differentiation. Elife 7, 36158 (2018). https://doi.org/10.7554/eLife.36158
  84. Y. Liu, Y. Tian, Y. Tian, Y. Wang, W. Yang, Carbon-dot-based nanosensors for the detection of intracellular redox state. Adv. Mater. 27(44), 7156–7160 (2015). https://doi.org/10.1002/adma.201503662
  85. G. Kuang, Q. Zhang, S. He, Y. Wu, Y. Huang, Reduction-responsive disulfide linkage core-cross-linked polymeric micelles for site-specific drug delivery. Polym. Chem. 11(44), 7078–7086 (2020). https://doi.org/10.1039/d0py00987c
  86. M. Bien, S. Longen, N. Wagener, I. Chwalla, J.M. Herrmann et al., Mitochondrial disulfide bond formation is driven by intersubunit electron transfer in Erv1 and proofread by glutathione. Mol. Cell 37(4), 516–528 (2010). https://doi.org/10.1016/j.molcel.2010.01.017
  87. P. Jangili, N. Kong, J.H. Kim, J. Zhou, H. Liu et al., DNA-damage-response-targeting mitochondria-activated multifunctional prodrug strategy for self-defensive tumor therapy. Angew. Chem. 61(16), 202117075 (2022). https://doi.org/10.1002/anie.202117075
  88. A. Pompella, A. Visvikis, A. Paolicchi, V. De Tata, A.F. Casini, The changing faces of glutathione, a cellular protagonist. Biochem. Pharm. 66(8), 1499–1503 (2003). https://doi.org/10.1016/S0006-2952(03)00504-5
  89. X. Zhong, X. Wang, L. Cheng, Y. Tang, G. Zhan et al., GSH-depleted PtCu3 nanocages for chemodynamic-enhanced sonodynamic cancer therapy. Adv. Funct. Mater. 30(4), 1907954 (2020). https://doi.org/10.1002/adfm.201907954
  90. Y. Cong, H. Xiao, H. Xiong, Z. Wang, J. Ding et al., Dual drug backboned shattering polymeric theranostic nanomedicine for synergistic eradication of patient-derived lung cancer. Adv. Mater. 30(11), 1706220 (2018). https://doi.org/10.1002/adma.201706220
  91. Y. Yu, Q. Xu, S. He, H. Xiong, Q. Zhang et al., Recent advances in delivery of photosensitive metal-based drugs. Coord. Chem. Rev. 387, 154–179 (2019). https://doi.org/10.1016/j.ccr.2019.01.020
  92. Q. Zhang, G. Kuang, Y. Yu, X. Ding, H. Ren et al., Hierarchical microps delivering oxaliplatin and NLG 919 nanoprodrugs for local chemo-immunotherapy. ACS Appl. Mater. Interfaces 14(43), 48527–48539 (2022). https://doi.org/10.1021/acsami.2c16564
  93. W. Wang, Y. Jin, X. Liu, F. Chen, X. Zheng et al., Endogenous stimuli-activatable nanomedicine for immune theranostics for cancer. Adv. Funct. Mater. 31(26), 2100386 (2021). https://doi.org/10.1002/adfm.202100386
  94. X. Wang, X. Li, X. Liang, J. Liang, C. Zhang et al., ROS-responsive capsules engineered from green tea polyphenol-metal networks for anticancer drug delivery. J. Mater. Chem. B 6(7), 1000–1010 (2018). https://doi.org/10.1039/C7TB02688A
  95. J. Li, S. Wang, X. Lin, Y. Cao, Z. Cai et al., Red blood cell-mimic nanocatalyst triggering radical storm to augment cancer immunotherapy. Nano-Micro Lett. 14(1), 57 (2022). https://doi.org/10.1007/s40820-022-00801-z
  96. U.S. Srinivas, B.W.Q. Tan, B.A. Vellayappan, A.D. Jeyasekharan, ROS and the DNA damage response in cancer. Redox Biol. 25, 101084 (2019). https://doi.org/10.1016/j.redox.2018.101084
  97. E. Panieri, M.M. Santoro, ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 7(6), 2253–2253 (2016). https://doi.org/10.1038/cddis.2016.105
  98. Y. Guo, X. He, R.M. Zhao, H.Z. Yang, Z. Huang et al., Zn-dipicolylamine-based reactive oxygen species-responsive lipids for siRNA delivery and in vivo colitis treatment. Acta Biomater. 147, 287–298 (2022). https://doi.org/10.1016/j.actbio.2022.04.033
  99. N. Yang, W. Xiao, X. Song, W. Wang, X. Dong, Recent advances in tumor microenvironment hydrogen peroxide-responsive materials for cancer photodynamic therapy. Nano-Micro Lett. 12(1), 15 (2020). https://doi.org/10.1007/s40820-019-0347-0
  100. G. Saravanakumar, J. Kim, W.J. Kim, Reactive-oxygen-species-responsive drug delivery systems: promises and challenges. Adv. Sci. 4(1), 1600124 (2017). https://doi.org/10.1002/advs.201600124
  101. Z. Jiang, J. Chen, L. Cui, X. Zhuang, J. Ding et al., Advances in stimuli-responsive polypeptide nanogels. Small Meth. 2(3), 1700307 (2018). https://doi.org/10.1002/smtd.201700307
  102. L. Chen, X. Wang, Y. Yuan, R. Hu, Q. Chen et al., Photosensitizers with aggregation-induced emission and their biomedical applications. Eng. Reg. 3(1), 59–72 (2022). https://doi.org/10.1016/j.engreg.2022.01.005
  103. D. Luo, K.A. Carter, E.A. Molins, N.L. Straubinger, J. Geng et al., Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals. J. Control. Release 297, 39–47 (2019). https://doi.org/10.1016/j.jconrel.2019.01.030
  104. Y. Liu, X. Zhao, C. Zhao, H. Zhang, Y. Zhao, Responsive porous microcarriers with controllable oxygen delivery for wound healing. Small 15(21), 1901254 (2019). https://doi.org/10.1002/smll.201901254
  105. W. Tao, O.C. Farokhzad, Theranostic nanomedicine in the NIR-II window: classification, fabrication, and biomedical applications. Chem. Rev. 122(6), 5405–5407 (2022). https://doi.org/10.1021/acs.chemrev.2c00089
  106. N.J. Farrer, L. Salassa, P.J. Sadler, Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine. Dalt. Trans. 48(48), 10690–10701 (2009). https://doi.org/10.1039/B917753A
  107. Q. Zhang, G. Kuang, D. Zhou, Y. Qi, M. Wang et al., Photoactivated polyprodrug nanops for effective light-controlled Pt(IV) and siRNA codelivery to achieve synergistic cancer therapy. J. Mater. Chem. B 8(27), 5903–5911 (2020). https://doi.org/10.1039/d0tb01103g
  108. S.S. Lucky, K.C. Soo, Y. Zhang, Nanops in photodynamic therapy. Chem. Rev. 115(4), 1990–2042 (2015). https://doi.org/10.1021/cr5004198
  109. J. Ouyang, A. Xie, J. Zhou, R. Liu, L. Wang et al., Minimally invasive nanomedicine: nanotechnology in photo-/ultrasound-/radiation-/magnetism-mediated therapy and imaging. Chem. Soc. Rev. 51(12), 4996–5041 (2022). https://doi.org/10.1039/D1CS01148K
  110. S. Koo, M.G. Lee, A. Sharma, M. Li, X. Zhang et al., Harnessing GULT1-targeted pro-oxidant ascorbate for synergistic phototherapeutics. Angew. Chem. Int. Ed. 61(17), 202110832 (2022). https://doi.org/10.1002/anie.202110832
  111. J. Li, S. Song, J. Meng, L. Tan, X. Liu et al., 2D MOF periodontitis photodynamic ion therapy. J. Am. Chem. Soc. 143(37), 15427–15439 (2021). https://doi.org/10.1021/jacs.1c07875
  112. L. Zou, H. Wang, B. He, L. Zeng, T. Tan et al., Current approaches of photothermal therapy in treating cancer metastasis with nanotherapeutics. Theranostics 6(6), 762 (2016). https://doi.org/10.7150/thno.14988
  113. D. Wu, X. Shou, Y. Yu, X. Wang, G. Chen et al., Biologics-loaded photothermally dissolvable hyaluronic acid microneedle patch for psoriasis treatment. Adv. Funct. Mater. 32(47), 2205847 (2022). https://doi.org/10.1002/adfm.202205847
  114. Y. Ye, J. He, Y. Qiao, Y. Qi, H. Zhang et al., Mild temperature photothermal assisted anti-bacterial and anti-inflammatory nanosystem for synergistic treatment of post-cataract surgery endophthalmitis. Theranostics 10(19), 8541–8557 (2020). https://doi.org/10.7150/thno.46895
  115. Y. Zhu, P. Xu, X. Zhang, D. Wu, Emerging porous organic polymers for biomedical applications. Chem. Soc. Rev. 51(4), 1377–1414 (2022). https://doi.org/10.1039/d1cs00871d
  116. X. Liu, Q. Liu, X. He, G. Yang, X. Chen et al., NIR-II-enhanced single-atom-nanozyme for sustainable accelerating bacteria-infected wound healing. Appl. Surf. Sci. 612, 155866 (2023). https://doi.org/10.1016/j.apsusc.2022.155866
  117. Q. Shao, B. Xing, Photoactive molecules for applications in molecular imaging and cell biology. Chem. Soc. Rev. 39(8), 2835–2846 (2010). https://doi.org/10.1039/B915574K
  118. H.D. Bandara, S.C. Burdette, Photoisomerization in different classes of azobenzene. Chem. Soc. Rev. 41(5), 1809–1825 (2012). https://doi.org/10.1039/c1cs15179g
  119. R. Klajn, Spiropyran-based dynamic materials. Chem. Soc. Rev. 43(1), 148–184 (2014). https://doi.org/10.1039/c3cs60181a
  120. Z. Wang, G. Kuang, Z. Yu, A. Li, D. Zhou et al., Light-activatable dual prodrug polymer nanop for precise synergistic chemotherapy guided by drug-mediated computed tomography imaging. Acta Biomater. 94, 459–468 (2019). https://doi.org/10.1016/j.actbio.2019.05.047
  121. P. Wu, X. Wang, Z. Wang, W. Ma, J. Guo et al., Light-activatable prodrug and AIEgen copolymer nanop for dual-drug monitoring and combination therapy. ACS Appl. Mater. Interfaces 11(20), 18691–18700 (2019). https://doi.org/10.1021/acsami.9b02346
  122. Q. Zhang, X. Wang, G. Kuang, Y. Yu, Y. Zhao, Photopolymerized 3D printing scaffolds with Pt(IV) prodrug initiator for postsurgical tumor treatment. Research 2022, 9784510 (2022). https://doi.org/10.34133/2022/9784510
  123. Q. Zhang, X. Wang, G. Kuang, Y. Zhao, Pt(IV) prodrug initiated microps from microfluidics for tumor chemo-, photothermal and photodynamic combination therapy. Bioact. Mater. 24(3), 185–196 (2023). https://doi.org/10.1016/j.bioactmat.2022.12.020
  124. G. Kuang, H. Lu, S. He, H. Xiong, J. Yu et al., Near-infrared light-triggered polyprodrug/siRNA loaded upconversion nanops for multi-modality imaging and synergistic cancer therapy. Adv. Healthcare Mater. 10(20), 2100938 (2021). https://doi.org/10.1002/adhm.202100938
  125. H. Li, Q. Yao, F. Xu, Y. Li, D. Kim et al., An activatable AIEgen probe for high-fidelity monitoring of overexpressed tumor enzyme activity and its application to surgical tumor excision. Angew. Chem. Int. Ed. 132(25), 10272–10281 (2020). https://doi.org/10.1002/anie.202001675
  126. J. Mu, J. Lin, P. Huang, X. Chen, Development of endogenous enzyme-responsive nanomaterials for theranostics. Chem. Soc. Rev. 47(15), 5554–5573 (2018). https://doi.org/10.1039/C7CS00663B
  127. J. Hu, G. Zhang, S. Liu, Enzyme-responsive polymeric assemblies, nanops and hydrogels. Chem. Soc. Rev. 41(18), 5933–5949 (2012). https://doi.org/10.1039/C2CS35103J
  128. X. Wang, J. Hu, G. Zhang, S. Liu, Highly selective fluorogenic multianalyte biosensors constructed via enzyme-catalyzed coupling and aggregation-induced emission. J. Am. Chem. Soc. 136(28), 9890–9893 (2014). https://doi.org/10.1021/ja505278w
  129. N. Qiu, X. Liu, Y. Zhong, Z. Zhou, Y. Piao et al., Esterase-activated charge-reversal polymer for fibroblast-exempt cancer gene therapy. Adv. Mater. 28(48), 10613–10622 (2016). https://doi.org/10.1002/adma.201603095
  130. H. Li, Z. Qiu, F. Li, C. Wang, The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. Oncol. Lett. 14(5), 5865–5870 (2017). https://doi.org/10.3892/ol.2017.6924
  131. Z. Luo, Y. Dai, H. Gao, Development and application of hyaluronic acid in tumor targeting drug delivery. Acta Pharm. Sin. B 9(6), 1099–1112 (2019). https://doi.org/10.1016/j.apsb.2019.06.004
  132. K.Y. Choi, E.J. Jeon, H.Y. Yoon, B.S. Lee, J.H. Na et al., Theranostic nanops based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials 33(26), 6186–6193 (2012). https://doi.org/10.1016/j.biomaterials.2012.05.029
  133. H.T. Pham, N.L. Block, V.B. Lokeshwar, Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res. 57(4), 778–783 (1997). https://doi.org/10.1016/S0022-5347(01)62975-6
  134. W. Sun, Z. Gu, ATP-responsive drug delivery systems. Exp. Opin. Drug Deliv. 13(3), 311–314 (2016). https://doi.org/10.1517/17425247.2016.1140147
  135. J. Deng, A. Walther, ATP-responsive and ATP-fueled self-assembling systems and materials. Adv. Mater. 32(42), 2002629 (2020). https://doi.org/10.1002/adma.202002629
  136. J. Ouyang, Z. Tang, N. Farokhzad, N. Kong, N.Y. Kim et al., Ultrasound mediated therapy: recent progress and challenges in nanoscience. Nano Today 35, 100949 (2020). https://doi.org/10.1016/j.nantod.2020.100949
  137. H. Zhu, L. Zhang, S. Tong, C.M. Lee, H. Deshmukh et al., Spatial control of in vivo CRISPR-Cas9 genome editing via nanomagnets. Nat. Biomed. Eng. 3(2), 126–136 (2019). https://doi.org/10.1038/s41551-018-0318-7
  138. M.-Q. Zhu, L.-Q. Wang, G.J. Exarhos, A.D. Li, Thermosensitive gold nanops. J. Am. Chem. Soc. 126(9), 2656–2657 (2004). https://doi.org/10.1021/ja038544z
  139. T. Hu, Z. Gu, G.R. Williams, M. Strimaite, J. Zha et al., Layered double hydroxide-based nanomaterials for biomedical applications. Chem. Soc. Rev. 51(14), 6126–6176 (2022). https://doi.org/10.1039/d2cs00236a
  140. Y. Liang, H. Xu, Z. Li, A. Zhangji, B. Guo, Bioinspired injectable self-healing hydrogel sealant with fault-tolerant and repeated thermo-responsive adhesion for sutureless post-wound-closure and wound healing. Nano-Micro Lett. 14(1), 185 (2022). https://doi.org/10.1007/s40820-022-00928-z
  141. W. Zhou, X. Ma, J. Wang, X. Xu, O. Koivisto et al., Co-delivery CPT and PTX prodrug with a photo/thermo-responsive nanoplatform for triple-negative breast cancer therapy. Smart Med. 1(1), 20220036 (2022). https://doi.org/10.1002/SMMD.20220036
  142. H. Nakatsuji, T. Numata, N. Morone, S. Kaneko, Y. Mori et al., Thermosensitive ion channel activation in single neuronal cells by using surface-engineered plasmonic nanops. Angew. Chem. Int. Ed. 54(40), 11725–11729 (2015). https://doi.org/10.1002/ange.201505534
  143. B. Zhao, Y. Zhuang, Z. Liu, J. Mao, S. Qian et al., Regulated extravascular microenvironment via reversible thermosensitive hydrogel for inhibiting calcium influx and vasospasm. Bioact. Mater. 21(3), 422–435 (2023). https://doi.org/10.1016/j.bioactmat.2022.08.024
  144. S. Qi, P. Zhang, M. Ma, M. Yao, J. Wu et al., Cellular internalization-induced aggregation of porous silicon nanops for ultrasound imaging and protein-mediated protection of stem cells. Small 15(1), 1804332 (2019). https://doi.org/10.1002/smll.201804332
  145. W. Chen, C. Liu, X. Ji, J. Joseph, Z. Tang et al., Stanene-based nanosheets for β-elemene delivery and ultrasound-mediated combination cancer therapy. Angew. Chem. Int. Ed. 60(13), 7155–7164 (2021). https://doi.org/10.1002/anie.202016330
  146. N. Lee, D. Yoo, D. Ling, M.H. Cho, T. Hyeon et al., Iron oxide based nanops for multimodal imaging and magnetoresponsive therapy. Chem. Rev. 115(19), 10637–10689 (2015). https://doi.org/10.1021/acs.chemrev.5b00112
  147. J.S. Ebersole, Magnetoencephalography/magnetic source imaging in the assessment of patients with epilepsy. Epilepsia 38, S1–S5 (1997). https://doi.org/10.1111/j.1528-1157.1997.tb04533.x
  148. J. Yang, X. Zhang, C. Liu, Z. Wang, L. Deng et al., Biologically modified nanops as theranostic bionanomaterials. Prog. Mater. Sci. 118, 100768 (2021). https://doi.org/10.1016/j.pmatsci.2020.100768
  149. Y. Shen, Z. Zhou, M. Sui, J. Tang, P. Xu et al., Charge-reversal polyamidoamine dendrimer for cascade nuclear drug delivery. Nanomedicine 5(8), 1205–1217 (2010). https://doi.org/10.2217/nnm.10.86
  150. R. Mo, Z. Gu, Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery. Mater. Today 19(5), 274–283 (2016). https://doi.org/10.1016/j.mattod.2015.11.025
  151. Y. Liu, Y. Zou, C. Feng, A. Lee, J. Yin et al., Charge conversional biomimetic nanocomplexes as a multifunctional platform for boosting orthotopic glioblastoma RNAi therapy. Nano Lett. 20(3), 1637–1646 (2020). https://doi.org/10.1021/acs.nanolett.9b04683
  152. M. Xu, D. Zhao, Y. Chen, C. Chen, L. Zhang et al., Charge reversal polypyrrole nanocomplex-mediated gene delivery and photothermal therapy for effectively treating papillary thyroid cancer and inhibiting lymphatic metastasis. ACS Appl. Mater. Interfaces 14(12), 14072–14086 (2022). https://doi.org/10.1021/acsami.1c25179
  153. C.Y. Sun, S. Shen, C.F. Xu, H.J. Li, Y. Liu et al., Tumor acidity-sensitive polymeric vector for active targeted siRNA delivery. J. Am. Chem. Soc. 137(48), 15217–15224 (2015). https://doi.org/10.1021/jacs.5b09602
  154. Q. Liu, K. Zhao, C. Wang, Z. Zhang, C. Zheng et al., Multistage delivery nanop facilitates efficient CRISPR/dCas9 activation and tumor growth suppression in vivo. Adv. Sci. 6(1), 1801423 (2019). https://doi.org/10.1002/advs.201801423
  155. Y. Qi, H. Song, H. Xiao, G. Cheng, B. Yu et al., Fluorinated acid-labile branched hydroxyl-rich nanosystems for flexible and robust delivery of plasmids. Small 14(42), 1803061 (2018). https://doi.org/10.1002/smll.201803061
  156. H. Yu, C. Guo, B. Feng, J. Liu, X. Chen et al., Triple-layered pH-responsive micelleplexes loaded with siRNA and cisplatin prodrug for NF-Kappa B targeted treatment of metastatic breast cancer. Theranostics 6(1), 14–27 (2016). https://doi.org/10.7150/thno.13515
  157. Q. Chen, T. Sun, C. Jiang, Recent advancements in nanomedicine for ‘cold’ tumor immunotherapy. Nano-Micro Lett. 13(1), 92 (2021). https://doi.org/10.1007/s40820-021-00622-6
  158. D. Kim, Y. Wu, Q. Li, Y.-K. Oh, Nanop-mediated lipid metabolic reprogramming of T cells in tumor microenvironments for immunometabolic therapy. Nano-Micro Lett. 13(1), 31 (2021). https://doi.org/10.1007/s40820-020-00555-6
  159. G. Kuang, Q. Zhang, Y. Yu, X. Ding, W. Sun et al., Lyophilization-inactivated cancer cells composited Janus scaffold for tumor postoperative immuno-chemotherapy. Chem. Eng. J. (2022). https://doi.org/10.1016/j.cej.2022.140619
  160. D. Wang, T. Wang, J. Liu, H. Yu, S. Jiao et al., Acid-activatable versatile micelleplexes for PD-L1 blockade-enhanced cancer photodynamic immunotherapy. Nano Lett. 16(9), 5503–5513 (2016). https://doi.org/10.1021/acs.nanolett.6b01994
  161. Y. Zou, X. Sun, Y. Wang, C. Yan, Y. Liu et al., Single siRNA nanocapsules for effective siRNA brain delivery and glioblastoma treatment. Adv. Mater. 32(24), 2000416 (2020). https://doi.org/10.1002/adma.202000416
  162. Y.X. Lin, Y. Wang, H.W. An, B. Qi, J. Wang et al., Peptide-based autophagic gene and cisplatin co-delivery systems enable improved chemotherapy resistance. Nano Lett. 19(5), 2968–2978 (2019). https://doi.org/10.1021/acs.nanolett.9b00083
  163. Q. Zhang, G. Kuang, S. He, S. Liu, H. Lu et al., Chain-shattering Pt(IV)-backboned polymeric nanoplatform for efficient CRISPR/Cas9 gene editing to enhance synergistic cancer therapy. Nano Res. 14(3), 601–610 (2020). https://doi.org/10.1007/s12274-020-3066-4
  164. H. Yang, R. Liu, Y. Xu, L. Qian, Z. Dai, Photosensitizer nanops boost photodynamic therapy for pancreatic cancer treatment. Nano-Micro Lett. 13(1), 35 (2021). https://doi.org/10.1007/s40820-020-00561-8
  165. X. Liu, J. Xiang, D. Zhu, L. Jiang, Z. Zhou et al., Fusogenic reactive oxygen species triggered charge-reversal vector for effective gene delivery. Adv. Mater. 28(9), 1743–1752 (2016). https://doi.org/10.1002/adma.201504288
  166. D.V. Schaffer, N.A. Fidelman, N. Dan, D.A. Lauffenburger, Vector unpacking as a potential barrier for receptor-mediated polyplex gene delivery. Biotechnol. Bioeng. 67(5), 598–606 (2000). https://doi.org/10.1002/(SICI)1097-0290(20000305)67:5%3c598::AID-BIT10%3e3.0.CO;2-G
  167. J. Zabner, A.J. Fasbender, T. Moninger, K.A. Poellinger, M.J. Welsh, Cellular and molecular barriers to gene transfer by a cationic lipid. J. Biolog. Chem. 270(32), 18997–19007 (1995). https://doi.org/10.1074/jbc.270.32.18997
  168. M. Piest, J.F. Engbersen, Effects of charge density and hydrophobicity of poly (amido amine)s for non-viral gene delivery. J. Control. Release 148(1), 83–90 (2010). https://doi.org/10.1016/j.jconrel.2010.07.109
  169. H. Pollard, J.-S. Remy, G. Loussouarn, S. Demolombe, J.-P. Behr et al., Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J. Biolog. Chem. 273(13), 7507–7511 (1998). https://doi.org/10.1074/jbc.273.13.7507
  170. D. Zhu, H. Yan, X. Liu, J. Xiang, Z. Zhou et al., Intracellularly disintegratable polysulfoniums for efficient gene delivery. Adv. Funct. Mater. 27(16), 1606826 (2017). https://doi.org/10.1002/adfm.201606826
  171. M. Zheng, Y. Liu, Y. Wang, D. Zhang, Y. Zou et al., ROS-responsive polymeric siRNA nanomedicine stabilized by triple interactions for the robust glioblastoma combinational RNAi therapy. Adv. Mater. 31(37), 1903277 (2019). https://doi.org/10.1002/adma.201903277
  172. M. Tavakkoli Yaraki, B. Liu, Y.N. Tan, Emerging strategies in enhancing singlet oxygen generation of nano-photosensitizers toward advanced phototherapy. Nano-Micro Lett. 14(1), 123 (2022). https://doi.org/10.1007/s40820-022-00856-y
  173. X. Zhang, L. Cheng, Y. Lu, J. Tang, Q. Lv et al., A MXene-based bionic cascaded-enzyme nanoreactor for tumor phototherapy/enzyme dynamic therapy and hypoxia-activated chemotherapy. Nano-Micro Lett. 14(1), 22 (2021). https://doi.org/10.1007/s40820-021-00761-w
  174. Q. Zhang, G. Kuang, S. He, H. Lu, Y. Cheng et al., Photoactivatable prodrug-backboned polymeric nanops for efficient light-controlled gene delivery and synergistic treatment of platinum-resistant ovarian cancer. Nano Lett. 20(5), 3039–3049 (2020). https://doi.org/10.1021/acs.nanolett.9b04981
  175. P.D. Hsu, E.S. Lander, F. Zhang, Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6), 1262–1278 (2014). https://doi.org/10.1016/j.cell.2014.05.010
  176. Y. Pan, J. Yang, X. Luan, X. Liu, X. Li et al., Near-infrared upconversion-activated CRISPR-Cas9 system: a remote-controlled gene editing platform. Sci. Adv. 5(4), 1eaav799 (2019). https://doi.org/10.1126/sciadv.aav7199
  177. J.B. van Beilen, Z. Li, Enzyme technology: an overview. Curr. Opin. Biotechnol. 13(4), 338–344 (2002). https://doi.org/10.1016/S0958-1669(02)00334-8
  178. M. Shahriari, M. Zahiri, K. Abnous, S.M. Taghdisi, M. Ramezani et al., Enzyme responsive drug delivery systems in cancer treatment. J. Control. Release 308, 172–189 (2019). https://doi.org/10.1016/j.jconrel.2019.07.004
  179. Y. Yi, M. Yu, C. Feng, H. Hao, W. Zeng et al., Transforming “cold” tumors into “hot” ones via tumor-microenvironment-responsive siRNA micelleplexes for enhanced immunotherapy. Matter 5(7), 2285–2305 (2022). https://doi.org/10.1016/j.matt.2022.04.032
  180. P. Wang, L. Zhang, W. Zheng, L. Cong, Z. Guo et al., Thermo-triggered release of CRISPR-Cas9 system by lipid-encapsulated gold nanops for tumor therapy. Angew. Chem. Int. Ed. 57(6), 1491–1496 (2018). https://doi.org/10.1002/anie.201708689
  181. Y. Pu, H. Yin, C. Dong, H. Xiang, W. Wu et al., Sono-controllable and ROS-sensitive CRISPR-Cas9 genome editing for augmented/synergistic ultrasound tumor nanotherapy. Adv. Mater. 33(45), 2104641 (2021). https://doi.org/10.1002/adma.202104641
  182. T. Fang, X. Cao, M. Ibnat, G. Chen, Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing. J. Nanobiotechnol. 20(1), 354 (2022). https://doi.org/10.1186/s12951-022-01570-y
  183. M. Naeem, S. Majeed, M.Z. Hoque, I. Ahmad, Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing. Cells 9(7), 1608 (2020). https://doi.org/10.3390/cells9071608
  184. M.N. Hsu, Y.C. Hu, Local magnetic activation of CRISPR. Nat. Biomed. Eng. 3(2), 83–84 (2019). https://doi.org/10.1038/s41551-019-0354-y
  185. O.O. Abudayyeh, J.S. Gootenberg, S. Konermann, J. Joung, I.M. Slaymaker et al., C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353(6299), aaf5573 (2016). https://doi.org/10.1126/science.aaf5573
  186. Z. Zhang, Q. Wang, Q. Liu, Y. Zheng, C. Zheng et al., Dual-locking nanops disrupt the PD-1/PD-L1 pathway for efficient cancer immunotherapy. Adv. Mater. 31(51), 1905751 (2019). https://doi.org/10.1002/adma.201905751
  187. J. Gilleron, W. Querbes, A. Zeigerer, A. Borodovsky, G. Marsico et al., Image-based analysis of lipid nanop-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31(7), 638–646 (2013). https://doi.org/10.1038/nbt.2612
  188. D.J. Glover, D.L. Leyton, G.W. Moseley, D.A. Jans, The efficiency of nuclear plasmid DNA delivery is a critical determinant of transgene expression at the single cell level. J. Gene Med. 12(1), 77–85 (2010). https://doi.org/10.1002/jgm.1406
  189. S. Hama, H. Akita, R. Ito, H. Mizuguchi, T. Hayakawa et al., Quantitative comparison of intracellular trafficking and nuclear transcription between adenoviral and lipoplex systems. Mol. Ther. 13(4), 786–794 (2006). https://doi.org/10.1016/j.ymthe.2005.10.007
  190. S. Wilhelm, A.J. Tavares, Q. Dai, S. Ohta, J. Audet et al., Analysis of nanop delivery to tumours. Nat. Rev. Mater. 1(5), 1–12 (2016). https://doi.org/10.1038/natrevmats.2016.14
  191. P. Zhang, Y. Xiao, X. Sun, X. Lin, S. Koo et al., Cancer nanomedicine toward clinical translation: obstacles, opportunities, and future prospects. Med (2022). https://doi.org/10.1016/j.medj.2022.12.001
Read More
Author biographies are not available.
Download this PDF file
PDF
Statistic
Read Counter : 3145 Download : 2376

Most read articles by the same author(s)